KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Cost of Revenue: 2011-2024

Historic Cost of Revenue for Novavax (NVAX) over the last 7 years, with Dec 2024 value amounting to $202.7 million.

  • Novavax's Cost of Revenue fell 64.54% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.6 million, marking a year-over-year decrease of 72.71%. This contributed to the annual value of $202.7 million for FY2024, which is 41.02% down from last year.
  • As of FY2024, Novavax's Cost of Revenue stood at $202.7 million, which was down 41.02% from $343.8 million recorded in FY2023.
  • Over the past 5 years, Novavax's Cost of Revenue peaked at $902.6 million during FY2022, and registered a low of $202.7 million during FY2024.
  • Over the past 3 years, Novavax's median Cost of Revenue value was $343.8 million (recorded in 2023), while the average stood at $483.0 million.
  • Data for Novavax's Cost of Revenue shows a maximum YoY plummeted of 61.92% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Novavax's Cost of Revenue stood at $902.6 million in 2022, then tumbled by 61.92% to $343.8 million in 2023, then plummeted by 41.02% to $202.7 million in 2024.